Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Auxilium Reports $11.8M Loss

By R&D Editors | May 9, 2011

MALVERN, Pa. (AP) – Auxilium Pharmaceuticals Inc. reported a larger first-quarter loss as it conducted studies in hopes of getting its drug Xiaflex approved to treat more conditions.

Auxilium posted a loss of $11.8 million, or 25 cents per share, up from $8.6 million, or 18 cents per share, in the first quarter of 2010. Its revenue rose 8 percent, to $58.4 million from $45.5 million.

Analysts expected a loss of 24 cents per share and $61.1 million in revenue, according to FactSet.

Auxilium started marketing Xiaflex in March 2010. It is approved to treat Dupuytren’s contracture, a condition that makes the tendons of the hand thicken and shorten, causing the fingers to curve inward.

The company is running another late-stage trial to support an approval in Peyronie’s disease. Peyronie’s disease causes abnormal curvature of the penis. The company expects to report initial data from that study in the second quarter of 2012.

The company said its research and development costs rose 86 percent to $15.8 million in the first quarter.

Sales of Xiaflex rose to $12.3 million from $1.3 million, including $1.8 million from recognition of deferred revenue. Revenue from the testosterone gel Testim grew 4 percent to $46.1 million.

During the quarter, Auxilium licensed the Japanese rights to Xiaflex to Asahi Kasei Pharma for $15 million. Auxilium has received that payment, and it is awaiting a $30 million payment from its partner Pfizer Inc., which holds the European rights to Xiaflex. Pfizer will make the payment after the first sale of Xiaflex in the U.K.

Auxilium could get another $30 million in payments after the drug goes on sale in other major European markets.

Based on those payments, Auxilium expects a smaller annual loss and greater revenue. It now forecasts a loss of $31 million to $41 million and $259 million to $281 million in total revenue. The company had projected a loss of $35 million to $45 million on $255 million to $277 million in revenue.

Analysts had projected Auxilium would lose $35.3 million, or 72 cents per share, on $270.5 million in revenue.

Date: May 9, 2011
Source: Associated Press

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE